Merck discontinue development of CB-1 agonist taranabant « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
October 2008

M T W T F S S

« Sep Nov »

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

Merck discontinue development of CB-1 agonist taranabant

Posted on October 2, 2008 by crimsoncanary

Merck has discontinued dvelopment of Cannabinoid 1 agonist Taranabant for Obesity due to adverse events

Filed under: Uncategorized | Tagged: Cannabinoid CB1, CB-1, CB1, Merck, taranabant

« Aeterna Zentaris reaches 2nd stage recruitment for AEZS-108 in Phase II ovarian cancer trial Emispheres GLP-1 safe after oral delivery »

Leave a Reply